Sequential Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Cascinu S, Graziano F, Barni S, Labianca R, Comella G, Casaretti R, Frontini L, Catalano V, Baldelli A M, Catalano G
Primary Institution: Division of Medical Oncology, Azienda Ospedale di Parma, Italy
Hypothesis
Can sequential chemotherapy with docetaxel after the PELF regimen improve outcomes in advanced gastric cancer?
Conclusion
The study found that sequential chemotherapy with docetaxel after the PELF regimen resulted in a significant overall response rate with manageable toxicity.
Supporting Evidence
- 40 patients were enrolled and evaluable for response and toxicity.
- After the PELF regimen, 3 patients achieved complete response and 13 showed partial response.
- The overall response rate in the 40 patients was 57.5%.
Takeaway
Doctors tested a new way to treat stomach cancer by giving patients two types of chemotherapy one after the other, and it helped many of them feel better.
Methodology
Patients received an initial PELF regimen followed by docetaxel if they had a partial response or stable disease.
Potential Biases
Potential bias due to the non-randomized design of the study.
Limitations
The study had a small sample size and was limited to patients with specific conditions.
Participant Demographics
Chemotherapy-naive patients with relapsed or metastatic gastric cancer.
Statistical Information
Confidence Interval
95% CI 25% to 55%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website